YOLFTbeta
NurExone Biologic Inc.

NurExone Biologic Inc.

NRX · V · Healthcare / Biotechnology

0.465CAD-0.02 (-4.12%)

Price History

Full chart

Market Stats

Previous Close0.485
Open0.485
Day Range0.465 – 0.485
52-Week Range0.435 – 1.09
Volume10.00K
Market Cap58.91M
P/E (TTM)0.00
Forward P/E6.90
EPS-0.10
Dividend Yield0.00%
Beta0.45
50-Day Avg0.5613
200-Day Avg0.6028

About

NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It offers ExoPTEN, for treatment of acute spinal cord injuries. The company was founded in 2020 and is based in Toronto, Canada.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Lior Shaltiel Ph.D.
  • Employees0
  • Headquarters1 Adelaide Street East, Toronto, ON, Canada, M5C 2V9, Canada
  • Websitehttps://nurexone.com

Leadership

  • Mr. Yoram DruckerCo-Founder, VP of Strategic Development & Chairman · b. 1965
  • Dr. Lior Shaltiel Ph.D.CEO & Director
  • Mr. Eran Ovadya M.B.A.CFO, Financial Director & Secretary · b. 1983
  • Mr. Gabriel EldorCo-Founder & Business Development Manager
  • Prof. Shulamit Levenberg Ph.D.Co-Founder & Member of Scientific Advisory Board · b. 1963
  • Dr. Daniel Offen Ph.D.Co-Founder
  • Dr. Ram Petter M.B.A., Ph.D.Head of Operations
  • Dr. Tali Kizhner Ph.D.Director of Research & Development
  • Prof. Nahshon Knoller M.D.Head of the neurosurgery department at Shiba & Member of Scientific Advisory Board
  • Dr. Ina Sarel Ph.D.Head of CMC, Quality & Regulation

Financials

Income Statement

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue00000
Operating Income-1.71M-5.54M-3.66M-5.01M-6.32M
EBITDA--8.12M-3.60M-4.94M-6.17M
Net Income-1.65M-8.17M-3.64M-5.04M-6.38M
R&D573.00K1.39M1.54M1.87M2.64M
Interest Expense12.00K33.00K3.00K17.00K31.00K

Balance Sheet

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.84M2.79M2.17M2.44M4.08M
Total Liabilities1.66M698.00K1.98M680.00K1.32M
Total Equity1.18M2.10M189.00K1.76M2.76M
Cash2.21M2.46M541.00K700.00K2.14M

Cash Flow

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.23M-3.85M-2.94M-4.89M-4.51M
Financing Cash Flow3.46M4.29M1.13M5.88M5.83M
Capital Expenditure052.00K120.00K649.00K55.00K
Free Cash Flow-1.23M-3.90M-3.06M-5.54M-4.57M
FCF to OCF100.00%101.35%104.08%113.28%101.22%

Earnings

Report DateAug 28, 2023Nov 24, 2023Dec 31, 2023May 29, 2024Nov 27, 2024Dec 31, 2024May 27, 2025Aug 27, 2025Nov 26, 2025Dec 31, 2025Apr 16, 2026Aug 31, 2026Nov 25, 2026
EPS Estimate-0.02-0.02-0.02-0.02-0.03-0.02-0.02-0.02-0.02-0.02-0.02-0.02-0.01
EPS Actual-0.02-0.03-0.01-0.02-0.02-0.02-0.02-0.02-0.02-0.02-0.02-0.02-
Surprise0.00%-50.00%25.00%0.00%33.33%5.00%0.00%0.00%0.00%0.00%0.00%0.00%-
TimingPre-marketPre-market-Pre-marketPre-market-Pre-marketAfter-hoursAfter-hours-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap58.91M
Enterprise Value60.36M
Trailing P/E0.00
Forward P/E6.90
Price / Sales0.00
Price / Book34.82
EPS-0.10
Book Value0.0185
Revenue (TTM)0
Gross Profit (TTM)-1.44M
EBITDA-6.05M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-450.96%
Return on Assets-142.12%
Shares Outstanding92.05M
Shares Float91.89M
Beta0.45
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%